ESR1 and breast carcinoma: The experimental evidence shows that antiestrogen therapies targeting a mixed lineage of ERα+ breast cancers expressing both markers of normal luminal and basal epithelial cells are inadequate in limiting cancer cell proliferation, but are capable of inducing adaptive responses such as tumor cell plasticity that promote the emergence of basal tumor subtype with enhanced CSC self-renewal activity [12,16].